Athira Accounts Payable vs Common Stock Shares Outstanding Analysis

ATHA Stock

USD 0.44 0.05 12.82%

Athira Pharma financial indicator trend analysis is way more than just evaluating Athira Pharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Athira Pharma is a good investment. Please check the relationship between Athira Pharma Accounts Payable and its Common Stock Shares Outstanding accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.

Accounts Payable vs Common Stock Shares Outstanding

Accounts Payable vs Common Stock Shares Outstanding Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Athira Pharma Accounts Payable account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Athira Pharma's Accounts Payable and Common Stock Shares Outstanding is 0.47. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Athira Pharma, assuming nothing else is changed. The correlation between historical values of Athira Pharma's Accounts Payable and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Athira Pharma are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Accounts Payable i.e., Athira Pharma's Accounts Payable and Common Stock Shares Outstanding go up and down completely randomly.

Correlation Coefficient

0.47

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Athira Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Athira Pharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most indicators from Athira Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Athira Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.The current year's Selling General Administrative is expected to grow to about 40.2 M, whereas Enterprise Value Over EBITDA is forecasted to decline to (0.03).

	2022	2023	2024	2025 (projected)
Reconciled Depreciation	845K	969K	1.1M	631.1K
Cost Of Revenue	1.0M	969K	872.1K	899.2K

Reconciled Depreciation Cost Of Revenue

Athira Pharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Non Current Liabilities Other
Total Assets		0.78	0.59	0.62	1.0	0.79	0.97	-0.94	-0.62	0.6	0.93	0.85	0.48	0.45	0.81	0.99	0.94	0.83	1.0	-0.94	0.92	0.91	-0.2	1.0	0.99	0.72
Short Long Term Debt Total	0.78		0.75	0.77	0.76	0.91	0.81	-0.87	-0.77	0.48	0.88	0.45	0.64	-0.04	0.91	0.83	0.84	0.95	0.74	-0.8	0.79	0.86	0.28	0.76	0.83	0.91
Other Current Liab	0.59	0.75		1.0	0.56	0.73	0.7	-0.79	-0.98	0.15	0.78	0.09	0.98	-0.11	0.67	0.67	0.73	0.77	0.53	-0.8	0.77	0.81	0.55	0.56	0.67	0.83
Total Current Liabilities	0.62	0.77	1.0		0.59	0.75	0.72	-0.82	-0.99	0.21	0.81	0.13	0.97	-0.09	0.69	0.7	0.75	0.79	0.57	-0.82	0.79	0.84	0.53	0.59	0.7	0.84
Total Stockholder Equity	1.0	0.76	0.56	0.59		0.77	0.96	-0.93	-0.58	0.6	0.91	0.87	0.44	0.48	0.79	0.98	0.92	0.81	1.0	-0.93	0.91	0.89	-0.26	1.0	0.98	0.68
Other Liab	0.79	0.91	0.73	0.75	0.77		0.86	-0.83	-0.75	0.44	0.86	0.52	0.66	0.27	0.99	0.83	0.85	0.99	0.76	-0.84	0.88	0.88	0.22	0.77	0.83	0.81
Net Tangible Assets	0.97	0.81	0.7	0.72	0.96	0.86		-0.96	-0.73	0.49	0.97	0.75	0.61	0.4	0.86	0.99	0.98	0.88	0.95	-0.98	0.97	0.97	-0.02	0.96	0.99	0.81
Net Debt	-0.94	-0.87	-0.79	-0.82	-0.93	-0.83	-0.96		0.82	-0.49	-0.98	-0.63	-0.69	-0.19	-0.82	-0.97	-0.97	-0.88	-0.91	0.97	-0.94	-0.97	-0.09	-0.93	-0.97	-0.88
Retained Earnings	-0.62	-0.77	-0.98	-0.99	-0.58	-0.75	-0.73	0.82		-0.2	-0.82	-0.13	-0.96	0.1	-0.7	-0.7	-0.76	-0.79	-0.55	0.82	-0.8	-0.85	-0.57	-0.58	-0.7	-0.87
Accounts Payable	0.6	0.48	0.15	0.21	0.6	0.44	0.49	-0.49	-0.2		0.48	0.68	0.03	0.33	0.49	0.56	0.36	0.47	0.6	-0.48	0.54	0.48	-0.2	0.6	0.56	0.32
Cash	0.93	0.88	0.78	0.81	0.91	0.86	0.97	-0.98	-0.82	0.48		0.62	0.68	0.18	0.85	0.97	0.98	0.89	0.89	-0.96	0.95	0.99	0.16	0.91	0.97	0.92
Non Current Assets Total	0.85	0.45	0.09	0.13	0.87	0.52	0.75	-0.63	-0.13	0.68	0.62		-0.02	0.72	0.58	0.78	0.66	0.54	0.88	-0.66	0.67	0.6	-0.61	0.87	0.78	0.3
Non Currrent Assets Other	0.48	0.64	0.98	0.97	0.44	0.66	0.61	-0.69	-0.96	0.03	0.68	-0.02		-0.1	0.6	0.55	0.63	0.69	0.42	-0.73	0.7	0.73	0.59	0.44	0.56	0.74
Other Assets	0.45	-0.04	-0.11	-0.09	0.48	0.27	0.4	-0.19	0.1	0.33	0.18	0.72	-0.1		0.31	0.36	0.26	0.24	0.49	-0.36	0.42	0.24	-0.65	0.48	0.36	-0.19
Long Term Debt	0.81	0.91	0.67	0.69	0.79	0.99	0.86	-0.82	-0.7	0.49	0.85	0.58	0.6	0.31		0.83	0.84	0.99	0.78	-0.83	0.87	0.87	0.16	0.79	0.84	0.78
Cash And Short Term Investments	0.99	0.83	0.67	0.7	0.98	0.83	0.99	-0.97	-0.7	0.56	0.97	0.78	0.55	0.36	0.83		0.97	0.87	0.98	-0.96	0.94	0.95	-0.08	0.98	1.0	0.8
Net Receivables	0.94	0.84	0.73	0.75	0.92	0.85	0.98	-0.97	-0.76	0.36	0.98	0.66	0.63	0.26	0.84	0.97		0.88	0.91	-0.95	0.93	0.96	0.06	0.92	0.97	0.87
Common Stock Shares Outstanding	0.83	0.95	0.77	0.79	0.81	0.99	0.88	-0.88	-0.79	0.47	0.89	0.54	0.69	0.24	0.99	0.87	0.88		0.8	-0.88	0.9	0.91	0.2	0.81	0.87	0.83
Short Term Investments	1.0	0.74	0.53	0.57	1.0	0.76	0.95	-0.91	-0.55	0.6	0.89	0.88	0.42	0.49	0.78	0.98	0.91	0.8		-0.92	0.89	0.87	-0.29	1.0	0.98	0.66
Non Current Liabilities Total	-0.94	-0.8	-0.8	-0.82	-0.93	-0.84	-0.98	0.97	0.82	-0.48	-0.96	-0.66	-0.73	-0.36	-0.83	-0.96	-0.95	-0.88	-0.92		-0.98	-0.97	-0.05	-0.93	-0.97	-0.8
Other Current Assets	0.92	0.79	0.77	0.79	0.91	0.88	0.97	-0.94	-0.8	0.54	0.95	0.67	0.7	0.42	0.87	0.94	0.93	0.9	0.89	-0.98		0.98	0.1	0.91	0.95	0.79
Other Stockholder Equity	0.91	0.86	0.81	0.84	0.89	0.88	0.97	-0.97	-0.85	0.48	0.99	0.6	0.73	0.24	0.87	0.95	0.96	0.91	0.87	-0.97	0.98		0.21	0.89	0.95	0.9
Total Liab	-0.2	0.28	0.55	0.53	-0.26	0.22	-0.02	-0.09	-0.57	-0.2	0.16	-0.61	0.59	-0.65	0.16	-0.08	0.06	0.2	-0.29	-0.05	0.1	0.21		-0.26	-0.08	0.49
Net Invested Capital	1.0	0.76	0.56	0.59	1.0	0.77	0.96	-0.93	-0.58	0.6	0.91	0.87	0.44	0.48	0.79	0.98	0.92	0.81	1.0	-0.93	0.91	0.89	-0.26		0.98	0.68
Total Current Assets	0.99	0.83	0.67	0.7	0.98	0.83	0.99	-0.97	-0.7	0.56	0.97	0.78	0.56	0.36	0.84	1.0	0.97	0.87	0.98	-0.97	0.95	0.95	-0.08	0.98		0.8
Non Current Liabilities Other	0.72	0.91	0.83	0.84	0.68	0.81	0.81	-0.88	-0.87	0.32	0.92	0.3	0.74	-0.19	0.78	0.8	0.87	0.83	0.66	-0.8	0.79	0.9	0.49	0.68	0.8

Click cells to compare fundamentals

Athira Pharma Account Relationship Matchups

Athira Pharma fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	279.6M	332.0M	258.2M	160.2M	184.3M	190.1M
Short Long Term Debt Total	1M	1.9M	1.9M	1.6M	1.8M	1.6M
Other Current Liab	3.0M	8.1M	18.3M	28.3M	32.6M	34.2M
Total Current Liabilities	4.4M	9.3M	21.4M	28.8M	33.2M	34.8M
Total Stockholder Equity	274.3M	321.1M	235.1M	130.2M	149.7M	169.8M
Net Tangible Assets	(19.7M)	274.3M	321.1M	235.1M	270.4M	175.1M
Net Debt	(59.6M)	(108.6M)	(94.1M)	(89.0M)	(80.1M)	(84.1M)
Retained Earnings	(41.0M)	(95.9M)	(191.5M)	(309.2M)	(278.3M)	(264.4M)
Accounts Payable	1.2M	567K	2.5M	129K	148.4K	140.9K
Cash	60.6M	110.5M	96.0M	90.6M	104.2M	66.6M
Non Current Assets Total	87.2M	71.2M	50.6M	5.5M	6.3M	6.0M
Non Currrent Assets Other	132K	56K	475K	1.1M	1.2M	1.3M
Other Assets	84.6M	5.3M	0.0	1.0	0.9	0.86
Cash And Short Term Investments	184.7M	253.8M	200.3M	147.4M	169.5M	145.4M
Net Receivables	1.3M	2.3M	1.2M	1.6M	1.9M	1.2M
Common Stock Shares Outstanding	32.5M	36.9M	37.7M	38.0M	43.7M	33.7M
Short Term Investments	124.1M	143.2M	104.4M	56.8M	65.4M	78.8M
Liabilities And Stockholders Equity	279.6M	332.0M	258.2M	160.2M	184.3M	190.1M
Non Current Liabilities Total	876K	1.6M	1.6M	1.2M	1.1M	1.0M
Other Current Assets	6.4M	4.7M	6.0M	5.7M	6.5M	4.2M
Other Stockholder Equity	315.3M	417.4M	428.6M	439.7M	505.7M	294.0M
Total Liab	5.3M	10.9M	23.0M	30.1M	34.6M	20.4M
Net Invested Capital	274.3M	321.1M	235.1M	130.2M	149.7M	170.2M
Total Current Assets	192.3M	260.8M	207.5M	154.7M	177.9M	150.8M
Non Current Liabilities Other	1.0M	876K	1.6M	1.6M	1.8M	1.3M
Net Working Capital	187.9M	251.5M	186.1M	125.9M	144.8M	138.7M
Accumulated Other Comprehensive Income	33K	(388K)	(2.0M)	(349K)	(401.4K)	(421.4K)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

When determining whether Athira Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Athira Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Athira Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Athira Pharma Stock:

How To Invest In Athira

Details

Is Athira Stock a good investment?

Details

What is Athira Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.

You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.20)

Return On Assets

(0.52)

Return On Equity

(1.03)

The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Athira Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Athira Accounts Payable vs Common Stock Shares Outstanding Analysis

Accounts Payable vs Common Stock Shares Outstanding

Accounts Payable vs Common Stock Shares Outstanding Correlation Analysis

Correlation Coefficient

Accounts Payable

Common Stock Shares Outstanding

Athira Pharma fundamental ratios Correlations

Athira Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Athira Pharma fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Short Term Investments	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity

Retained Earnings	- 0.99	Total Current Liabilities
Other Current Assets	- 0.98	Non Current Liabilities Total
Cash	- 0.98	Net Debt
Non Current Liabilities Total	- 0.98	Net Tangible Assets
Retained Earnings	- 0.98	Other Current Liab
Total Current Assets	- 0.97	Non Current Liabilities Total